| Pay vs Performance Disclosure - USD ($) | 12 Months Ended |
| Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
| Pay vs Performance Disclosure | | | | |
| Pay vs Performance Disclosure, Table | Value of Initial Fixed $100 Investment Based on: Year Summary Compensation Table Total for PEO ($)(1) Compensation Actually Paid to PEO ($)(2) Average Summary Compensation Table Total for Non-PEO Named Executive Officers ($)(1) Average Compensation Actually Paid to Non-PEO Named Executive Officers ($)(2) Total Shareholder Return ($) Peer Group Total Shareholder Return ($)(3) Net Income (Loss) (in thousands) ($)(4) Total Revenue (in thousands) ($)(5) 2023 3,124,165 5,226,790 2,045,115 2,615,714 112.16 230.04 40,720 216,666 2022 3,916,032 (3,046,539) 1,568,352 187,840 58.55 56.52 (149,189) 180,955 2021 8,493,477 (21,063,411) 4,057,728 (2,628,730) 109.12 66.02 (101,219) 137,931 2020 8,510,593 72,690,646 2,353,326 16,840,839 248.06 237.01 (26,637) 108,095 | | | |
| Company Selected Measure Name | revenue | | | |
| Named Executive Officers, Footnote | Our PEO was Ramy Farid for all years in the table. Our Non-PEO named executive officers were: (i) for 2023, Geoffrey Porges, Karen Akinsanya, Robert Abel and Margaret Dugan; (ii) for 2022, Geoffrey Porges, Jenny Herman, Joel Lebowitz, Karen Akinsanya, Robert Abel, and Yvonne Tran; (iii) for 2021, Joel Lebowitz, Karen Akinsanya, Robert Abel, and Patrick Lorton; and (iv) for 2020, Karen Akinsanya and Yvonne Tran. | | | |
| Peer Group Issuers, Footnote | Reflects cumulative total shareholder return on the Nasdaq Biotechnology Index. The Nasdaq Biotechnology Index is used by us for purposes of Item 201(e) of Regulation S-K under the Exchange Act in our Annual Report on Form 10-K for the year ended December 31, 2023. | | | |
| PEO Total Compensation Amount | $ 3,124,165 | $ 3,916,032 | $ 8,493,477 | $ 8,510,593 |
| PEO Actually Paid Compensation Amount | $ 5,226,790 | (3,046,539) | (21,063,411) | 72,690,646 |
| Adjustment To PEO Compensation, Footnote | The dollar amounts reported in this column represent the amount of “compensation actually paid” to Dr. Farid and average “compensation actually paid” to our Non-PEO named executive officers, computed in accordance with Item 402(v) of Regulation S-K. In accordance with the requirements of Item 402(v) of Regulation S-K, the following prescribed adjustments were made to Dr. Farid’s and to our Non-PEO named executive officers’ total compensation as reported in the Summary Compensation Table for each year, to determine the amount of compensation actually paid. The Summary Compensation Table amounts and the “compensation actually paid” amounts do not reflect the actual amount of compensation earned by or paid to our executives during the applicable years, but rather are amounts determined in accordance with Item 402 of Regulation S-K under the Exchange Act. 2023 2022 2021 2020 PEO Average PEO Average PEO Average PEO Average Total Compensation from $ 3,124,165 $ 2,045,115 $ 3,916,032 $ 1,568,352 $ 8,493,477 $ 4,057,728 $ 8,510,593 $ 2,353,326 Adjustments for Equity Awards Subtract grant date fair value of equity awards reported in the Summary Compensation Table (2,067,787) (1,380,940) (2,877,355) (985,122) (7,470,776) (3,486,362) (7,499,672) (1,679,025) Add year-end fair value of awards granted in the covered year that are outstanding and unvested at covered year-end 3,378,111 1,465,301 1,995,200 674,500 1,843,500 860,300 57,702,506 12,918,426 Add year-over-year change in year-end fair values for awards granted in prior years that were outstanding and unvested at covered year-end 2,160,032 707,069 (3,800,546) (464,474) (24,233,997) (3,857,422) 11,068,483 2,646,935 Add fair value at vest date for awards granted and vested in covered year — — — — — — — — Add change in fair values between prior year-end fair values and vest date fair values for awards granted in prior years for which vesting conditions were satisfied during covered year (1,367,731) (220,831) (2,279,870) (302,116) 304,385 (202,974) 2,908,736 601,177 Subtract fair value at end of the prior year of awards granted in any prior year that failed to meet applicable vesting conditions in covered year — — — (303,300) — — — — Add dividends or other earnings paid on stock or option awards in the covered year prior to vesting if not otherwise included in the total compensation for the covered year — — — — — — — — Total Adjustments for Equity Awards $ 2,102,625 $ 570,599 $ (6,962,571) $ (1,380,512) $ (29,556,888) $ (6,686,458) $ 64,180,053 $ 14,487,513 Total “Compensation Actually Paid” $ 5,226,790 $ 2,615,714 $ (3,046,539) $ 187,840 $ (21,063,411) $ (2,628,730) $ 72,690,646 $ 16,840,839 * Amounts presented are averages for the entire group of Non-PEO named executive officers. | | | |
| Non-PEO NEO Average Total Compensation Amount | $ 2,045,115 | 1,568,352 | 4,057,728 | 2,353,326 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 2,615,714 | 187,840 | (2,628,730) | 16,840,839 |
| Adjustment to Non-PEO NEO Compensation Footnote | 2023 2022 2021 2020 PEO Average PEO Average PEO Average PEO Average Total Compensation from $ 3,124,165 $ 2,045,115 $ 3,916,032 $ 1,568,352 $ 8,493,477 $ 4,057,728 $ 8,510,593 $ 2,353,326 Adjustments for Equity Awards Subtract grant date fair value of equity awards reported in the Summary Compensation Table (2,067,787) (1,380,940) (2,877,355) (985,122) (7,470,776) (3,486,362) (7,499,672) (1,679,025) Add year-end fair value of awards granted in the covered year that are outstanding and unvested at covered year-end 3,378,111 1,465,301 1,995,200 674,500 1,843,500 860,300 57,702,506 12,918,426 Add year-over-year change in year-end fair values for awards granted in prior years that were outstanding and unvested at covered year-end 2,160,032 707,069 (3,800,546) (464,474) (24,233,997) (3,857,422) 11,068,483 2,646,935 Add fair value at vest date for awards granted and vested in covered year — — — — — — — — Add change in fair values between prior year-end fair values and vest date fair values for awards granted in prior years for which vesting conditions were satisfied during covered year (1,367,731) (220,831) (2,279,870) (302,116) 304,385 (202,974) 2,908,736 601,177 Subtract fair value at end of the prior year of awards granted in any prior year that failed to meet applicable vesting conditions in covered year — — — (303,300) — — — — Add dividends or other earnings paid on stock or option awards in the covered year prior to vesting if not otherwise included in the total compensation for the covered year — — — — — — — — Total Adjustments for Equity Awards $ 2,102,625 $ 570,599 $ (6,962,571) $ (1,380,512) $ (29,556,888) $ (6,686,458) $ 64,180,053 $ 14,487,513 Total “Compensation Actually Paid” $ 5,226,790 $ 2,615,714 $ (3,046,539) $ 187,840 $ (21,063,411) $ (2,628,730) $ 72,690,646 $ 16,840,839 * Amounts presented are averages for the entire group of Non-PEO named executive officers. | | | |
| Compensation Actually Paid vs. Total Shareholder Return | The following line chart presents a graphical comparison of executive compensation actually paid to our PEO and the average executive compensation actually paid to the Non-PEO named executive officers set forth in the Pay Versus Performance table above, as compared against the following performance measures: the Company's (1) cumulative total shareholder return, (2) peer group total shareholder return, (3) net income (loss), and (4) total revenue. For purposes of comparison, the Company’s cumulative total shareholder return and peer group total shareholder return in the following chart has been presented on a scaled basis, assuming an initial starting value of $100 in each instance. When reviewing the relationship between pay versus performance in the chart below, it is important to note that a substantial portion of our PEO and non-PEO named executive officers’ compensation consisted of stock options and/or RSUs with time-based vesting and PRSUs with performance-based vesting. As the compensation actually paid as calculated pursuant to Item 402(v) of Regulation S-K is based on the accounting changes in the fair value of such options, the value varies significantly with the performance of our common stock. Therefore, notwithstanding the increase in the Company’s total revenue (our most important financial performance measure that is not otherwise required to be disclosed in the table), the compensation actually paid to our PEO and the average compensation actually paid to our non-PEO named executive officers were heavily impacted by the Company’s total shareholder return. | | | |
| Compensation Actually Paid vs. Net Income | The following line chart presents a graphical comparison of executive compensation actually paid to our PEO and the average executive compensation actually paid to the Non-PEO named executive officers set forth in the Pay Versus Performance table above, as compared against the following performance measures: the Company's (1) cumulative total shareholder return, (2) peer group total shareholder return, (3) net income (loss), and (4) total revenue. For purposes of comparison, the Company’s cumulative total shareholder return and peer group total shareholder return in the following chart has been presented on a scaled basis, assuming an initial starting value of $100 in each instance. When reviewing the relationship between pay versus performance in the chart below, it is important to note that a substantial portion of our PEO and non-PEO named executive officers’ compensation consisted of stock options and/or RSUs with time-based vesting and PRSUs with performance-based vesting. As the compensation actually paid as calculated pursuant to Item 402(v) of Regulation S-K is based on the accounting changes in the fair value of such options, the value varies significantly with the performance of our common stock. Therefore, notwithstanding the increase in the Company’s total revenue (our most important financial performance measure that is not otherwise required to be disclosed in the table), the compensation actually paid to our PEO and the average compensation actually paid to our non-PEO named executive officers were heavily impacted by the Company’s total shareholder return. | | | |
| Compensation Actually Paid vs. Company Selected Measure | The following line chart presents a graphical comparison of executive compensation actually paid to our PEO and the average executive compensation actually paid to the Non-PEO named executive officers set forth in the Pay Versus Performance table above, as compared against the following performance measures: the Company's (1) cumulative total shareholder return, (2) peer group total shareholder return, (3) net income (loss), and (4) total revenue. For purposes of comparison, the Company’s cumulative total shareholder return and peer group total shareholder return in the following chart has been presented on a scaled basis, assuming an initial starting value of $100 in each instance. When reviewing the relationship between pay versus performance in the chart below, it is important to note that a substantial portion of our PEO and non-PEO named executive officers’ compensation consisted of stock options and/or RSUs with time-based vesting and PRSUs with performance-based vesting. As the compensation actually paid as calculated pursuant to Item 402(v) of Regulation S-K is based on the accounting changes in the fair value of such options, the value varies significantly with the performance of our common stock. Therefore, notwithstanding the increase in the Company’s total revenue (our most important financial performance measure that is not otherwise required to be disclosed in the table), the compensation actually paid to our PEO and the average compensation actually paid to our non-PEO named executive officers were heavily impacted by the Company’s total shareholder return. | | | |
| Total Shareholder Return Vs Peer Group | The following line chart presents a graphical comparison of executive compensation actually paid to our PEO and the average executive compensation actually paid to the Non-PEO named executive officers set forth in the Pay Versus Performance table above, as compared against the following performance measures: the Company's (1) cumulative total shareholder return, (2) peer group total shareholder return, (3) net income (loss), and (4) total revenue. For purposes of comparison, the Company’s cumulative total shareholder return and peer group total shareholder return in the following chart has been presented on a scaled basis, assuming an initial starting value of $100 in each instance. When reviewing the relationship between pay versus performance in the chart below, it is important to note that a substantial portion of our PEO and non-PEO named executive officers’ compensation consisted of stock options and/or RSUs with time-based vesting and PRSUs with performance-based vesting. As the compensation actually paid as calculated pursuant to Item 402(v) of Regulation S-K is based on the accounting changes in the fair value of such options, the value varies significantly with the performance of our common stock. Therefore, notwithstanding the increase in the Company’s total revenue (our most important financial performance measure that is not otherwise required to be disclosed in the table), the compensation actually paid to our PEO and the average compensation actually paid to our non-PEO named executive officers were heavily impacted by the Company’s total shareholder return. | | | |
| Tabular List, Table | Total revenue Progress of our collaborative and proprietary drug discovery programs Advancements in the science and technology underlying our platform | | | |
| Total Shareholder Return Amount | $ 112.16 | 58.55 | 109.12 | 248.06 |
| Peer Group Total Shareholder Return Amount | 230.04 | 56.52 | 66.02 | 237.01 |
| Net Income (Loss) | $ 40,720,000 | $ (149,189,000) | $ (101,219,000) | $ (26,637,000) |
| Company Selected Measure Amount | 216,666,000 | 180,955,000 | 137,931,000 | 108,095,000 |
| PEO Name | Ramy Farid | | | |
| Additional 402(v) Disclosure | The dollar amounts reported represent the amount of net income (loss) reflected in the Company’s audited financial statements for the applicable year. (5) In the Company’s assessment, total revenue is the financial performance measure that is the most important financial performance measure used by the Company for the most recently completed fiscal year, to link compensation actually paid to performance. | | | |
| Measure:: 1 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Total revenue | | | |
| Measure:: 2 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Progress of our collaborative and proprietary drug discovery programs | | | |
| Measure:: 3 | | | | |
| Pay vs Performance Disclosure | | | | |
| Name | Advancements in the science and technology underlying our platform | | | |
| PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | $ (2,067,787) | $ (2,877,355) | $ (7,470,776) | $ (7,499,672) |
| PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 2,102,625 | (6,962,571) | (29,556,888) | 64,180,053 |
| PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 3,378,111 | 1,995,200 | 1,843,500 | 57,702,506 |
| PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 2,160,032 | (3,800,546) | (24,233,997) | 11,068,483 |
| PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 |
| PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (1,367,731) | (2,279,870) | 304,385 | 2,908,736 |
| PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 |
| PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 |
| Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (1,380,940) | (985,122) | (3,486,362) | (1,679,025) |
| Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 570,599 | (1,380,512) | (6,686,458) | 14,487,513 |
| Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 1,465,301 | 674,500 | 860,300 | 12,918,426 |
| Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 707,069 | (464,474) | (3,857,422) | 2,646,935 |
| Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 |
| Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | (220,831) | (302,116) | (202,974) | 601,177 |
| Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | 0 | (303,300) | 0 | 0 |
| Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year | | | | |
| Pay vs Performance Disclosure | | | | |
| Adjustment to Compensation, Amount | $ 0 | $ 0 | $ 0 | $ 0 |
